A new subcutaneous formulation of the immunotherapy drug Tecentriq has been introduced in India, allowing lung cancer treatment to be administered in about seven minutes—potentially reducing hospital time by nearly 80 per cent and enabling more patients to receive therapy within the same clinical capacity.